Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics Q3 net loss widens to $48.0 million from $30.1 million

Negative Impact 3 of 5 earnings

Maze Therapeutics reported third quarter 2026 results with a net loss of $48.0 million, or $0.79 per share, up from $30.1 million, or $0.66 per share, a year earlier. The increase reflects higher research and development and general and administrative spending, and the company recognized no license revenue in the quarter, so shareholders face a larger loss with no revenue offset in the period.

Key points

  • Q3 2026 net loss was $48.0 million, or $0.79 per share, versus $30.1 million, or $0.66 per share, in Q3 2025.
  • R&D expenses rose to $40.2 million from $25.2 million, and G&A expenses rose to $11.3 million from $7.8 million.
  • Cash, cash equivalents and marketable securities were $477.0 million at September 30, 2026, up from $360.0 million at December 31, 2025, and are expected to fund operations into 2029.
  • Nine-month license revenue of $20.0 million reflects a first-quarter 2026 milestone under the Shionogi license for MZE001.

The filing

CompanyMaze Therapeutics, Inc. (MAZE)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:09 PM ET
Accession number0001193125-26-453590

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 6:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.